Cancer Translational Medicine is a peer-reviewed online journal with Bimonthly print on demand compilation of issues published. The journal is sponsored by Chinese Anti-Cancer Association (CACA) and American Chinese Medical Association (ACMA). It is owned by Xi'an Moshan Biotechnology and Information Co., Ltd. (http://www.moshanbio.com/). The journal’s full text is available online at http://www.cancertm.com. It allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository.
Abstracting and Indexing Information
The journal is registered with the following abstracting partners:
Baidu Scholar, CNKI (China National Knowledge Infrastructure), EBSCO Publishing's Electronic Databases, Exlibris – Primo Central, Google Scholar, Hinari, Infotrieve, National Science Library, ProQuest, TdNet
The journal is indexed with, or included in, the following:
Wolters Kluwer and Journal/Association are committed to meeting and upholding standards of ethical behavior at all stages of the publication process. We follow closely the industry associations, such as the Committee on Publication Ethics (COPE), International Committee of Medical Journal Editors (ICMJE) and World Association of Medical Editors (WAME), that set standards and provide guidelines for best practices in order to meet these requirements. For a summary of our specific policies regarding duplicate publication, conflicts of interest, patient consent, etc., please visit www.Medknow.com/EthicalGuidelines.asp
Open Access Publication and Creative Commons Licensing
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Wolters Kluwer Medknow provides for long-term digital preservation through two primary partnerships, Portico and CLOCKSS.
Portico is a leading digital preservation service worldwide. The content is preserved as an archival version and is not publically accessible via Portico, but is provided when required under specific conditions, such as discontinuation of the collection or catastrophic failure of the website.
CLOCKSS will enable any library to maintain their own archive of content from Wolters Kluwer Medknow and other publishers, with minimal technical effort and using cheaply available hardware.
Ahead of Print policy
Articles published online under the Ahead of Print model are considered published and can be cited and quoted using the DOI as the reference source. Wolters Kluwer Medknow has a policy that changes will not be made after publication of an article without following accepted procedures for making corrections to the scientific record.
While advertisements are crucial to this journal to be able to keep all content free for everyone, ethical considerations are in place to ensure the integrity of the journal and its content:
- "Pop-up" and "banner" ads appear on a random, rotating basis. The advertiser has no control or input over the pages where their ads appear.
- The Editorial Board has full and final approval over the content of all advertisements.
- Advertisers will never be shown any manuscripts or other content prior to publication.
The journal is sponsored by Chinese Anti-Cancer Association (CACA) and American Chinese Medical Association (ACMA). CACA was established in 1984. The vision of CACA is to be the leading non-governmental organization devoted to increase the survival rate, decrease the incidence and mortality rate of cancer, and improve the cancer control in China and the world. The mission of CACA is to contribute to the prevention and treatment of cancer via organizing, mobilizing and supporting clinical, scientific and technological professionals in the field of oncology.
ACMA was established in 1998. ACMA aims to be a premier American-Chinese academic medical organization. The mission of ACMA is to combine the power of Eastern and Western Medicine to improve health for all, promote healthcare delivery, medical education and training, and community service, bridge the gap between medical research and clinical practice, and function as a bridge for healthcare professionals between US and China.
The journal covers innovative basic, clinical and translational cancer research studies that bridge the laboratory and the clinic. Cancer Translational Medicine is especially interested in cancer risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and experimental therapeutics in the field of chemotherapy, radiotherapy and biotherapy (immune-therapy, gene-therapy, target-therapy, stem-cell-therapy and so on). Examples of content include:
- Translational, clinical, preventative, and epidemiologic cancer research
- Molecular and cellular level researches that reveal novel mechanistic insight into pathways and processes linked to cancer risk, development, and/or progression
- New molecular mechanisms and interactions that support cancer phenotypes
- An incisive rationale that could interest a broad audience
- A generalizable conclusion with potentially broad impact
Potential Audience: Researchers focus on basic and translational cancer study, physician scientists, students, funding agencies, business developers